Retatrutide has emerged as a new treatment in the fight against obesity. This novel drug, classified as a dual GLP-1 and GIP receptor agonist, exhibits promising results in clinical trials. By boosting these receptors, Retatrutide reduces hunger pangs, {promotesenergy expenditure, and ultimately res